Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Kurabayashi - if it was not considered by

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
rafunrafun Member Profile
 
Followed By 103
Posts 17,903
Boards Moderated 0
Alias Born 01/06/14
160x600 placeholder
Amarin jumps after activist Sarissa discloses stake in 13-F filing Seeking Alpha - 11/16/2021 10:52:48 AM
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021 GlobeNewswire Inc. - 11/16/2021 7:00:00 AM
Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scientific GlobeNewswire Inc. - 11/15/2021 4:30:00 PM
Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire Inc. - 11/11/2021 7:00:00 AM
Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021 GlobeNewswire Inc. - 11/8/2021 7:00:00 AM
Amarin shares fall after Q3 topline miss, cash position update Seeking Alpha - 11/3/2021 6:40:19 AM
Amarin EPS beats by $0.01, misses on revenue Seeking Alpha - 11/3/2021 6:03:17 AM
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 11/3/2021 6:00:00 AM
Amarin Q3 2021 Earnings Preview Seeking Alpha - 11/2/2021 11:36:18 AM
Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 GlobeNewswire Inc. - 10/20/2021 7:05:00 AM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/12/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:31:42 AM
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S. GlobeNewswire Inc. - 9/22/2021 9:15:00 AM
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany GlobeNewswire Inc. - 9/13/2021 7:00:00 AM
Amarin to Participate in September Investment Conferences GlobeNewswire Inc. - 9/13/2021 6:00:00 AM
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire Inc. - 8/31/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/30/2021 7:00:00 AM
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Societ... GlobeNewswire Inc. - 8/23/2021 3:15:00 AM
CEO Presenting on the Emerging Growth Conference on Tomorrow.  Register Now InvestorsHub NewsWire - 8/17/2021 7:00:00 AM
Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology GlobeNewswire Inc. - 8/16/2021 7:00:00 AM
HLS Therapeutics inks promotional agreement with Pfizer for Vascepa in Canada Seeking Alpha - 8/16/2021 6:55:44 AM
Amarin Q2 Earnings, Revenues Surpass Estimates TipRanks - 8/5/2021 9:58:38 AM
Amarin posts Q2 earnings beat, provides cash position update Seeking Alpha - 8/5/2021 7:58:34 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2021 6:09:55 AM
rafunrafun   Friday, 04/03/20 03:01:00 PM
Re: None
Post # of 362241 
Kurabayashi - if it was not considered by the USPTO, perhaps it was because it has no relevance to the MARINE patent? Just like Mori, not a single enrollee of Kurabayashi would have been eligible for MARINE trial.

Quote:
To assess the efficacy and safety of eicosapentaenoic acid for the treatment of hyperlipidemia in symptomatic menopausal Japanese women. We performed a prospective observational 48-week study in hyperlipidemic menopausal women. We randomly assigned 141 women, whose levels of serum total cholesterol were 220 to 280 mg/dL or whose serum triglycerides were 150 to 400 mg/dL at baseline to groups treated with estriol (E3) 2 mg daily (control group, n = 72) or ethyl icosapentate 1800 mg daily and E3 2 mg (eicosapentaenoic acid group, n = 69). Serum levels of total cholesterol decreased significantly from 249.4 to 238.6 mg/dL (-4.3%, P =.003) in the control group and from 252.3 to 234.0 mg/dL (-7.3%, P =.001) in the study group at week 48 in the women whose total cholesterol was not less than 220 mg/dL at baseline. Serum levels of triglycerides decreased significantly from 194.5 to 141.5 mg/dL (-27. 2%, P =.001) in the study group but increased slightly from 192.9 to 207.4 mg/dL (+7.5%) in the control group at week 48 in the women whose level of triglycerides was not less than 150 mg/dL. There were significant differences between these two groups at weeks 12, 24, and 48. Serum levels of total cholesterol and triglycerides were significantly decreased at week 48 in the study group regardless of whether the women were obese. There were no severe adverse effects. Combination therapy with eicosapentaenoic acid and E3 was effective and safe for menopausal women with hypertriglyceridemia.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences